Clinical Success of Different Percutaneous Transhepatic Biliary Drainage Procedures
Launched by THERESIENKRANKENHAUS UND ST. HEDWIG-KLINIK GMBH · Feb 24, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a medical procedure called percutaneous transhepatic biliary drainage (PTBD), which is used to help patients with extrahepatic cholestasis, a condition where bile cannot flow properly from the liver. The researchers want to find out if measuring a specific liver enzyme, called gamma-glutamyl transferase (GGT), is a better way to assess the success of PTBD compared to the usual method of checking bilirubin levels, which can be affected by other health issues.
To participate in this trial, individuals must be between the ages of 65 and 159 and have had a technically successful PTBD procedure. Those whose PTBD was not successful will not be eligible. Participants can expect to have their bilirubin and GGT levels monitored after the procedure to see how well it worked. This study could help improve how doctors evaluate the success of PTBD, ultimately leading to better care for patients with liver issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • technically successful PTBD
- Exclusion Criteria:
- • technically not successful PTBD
About Theresienkrankenhaus Und St. Hedwig Klinik Gmbh
Theresienkrankenhaus und St. Hedwig-Klinik GmbH is a leading healthcare institution based in Germany, renowned for its commitment to providing high-quality medical care and advancing clinical research. With a rich history of excellence in patient treatment and innovative medical practices, the organization conducts a range of clinical trials aimed at enhancing therapeutic options and improving health outcomes. Their multidisciplinary team of healthcare professionals collaborates closely with researchers to ensure rigorous adherence to ethical standards and regulatory compliance, fostering an environment that prioritizes patient safety and scientific integrity. Through its clinical trial initiatives, Theresienkrankenhaus und St. Hedwig-Klinik GmbH strives to contribute to the advancement of medical knowledge and the development of effective treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schwerin, , Germany
Patients applied
Trial Officials
Daniel Schmitz, MD
Principal Investigator
Theresienkrankenhaus Mannheim, University of Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials